Creation of TRIO-US

Print
Press Enter to show all options, press Tab go to next option

Historically, the UCLA Jonsson Comprehensive Cancer Center (JCCC) partnered with large private practices to offer oncology patients earlier access to leading-edge therapeutic trials. This organization consisted of sites affiliated under the JCCC. The name of this union of community practice was the Community Oncology Research Network (CORN).  In 1995, the organization formally the name to Translational Oncology Research International (TORI), established itself as a non-profit, 501c(3), and a site management organization (SMO). Subsequently, the name was changed in 2011 to Translational Research in Oncology-United States Network (TRIO-US) in alliance with international partner in TRIO. The Network operates under a Memorandum of Understanding (MOU) between the UCLA Chancellor’s Office and the JCCC stipulating the primary purpose of TRIO-US is to offer important and select cutting-edge therapeutic trials to participants outside the immediate catchment area and nationwide, which supports greater accrual to JCCC clinical trials. This arrangement has been particularly effective at giving JCCC investigators access to the wider potential patient pool needed to conduct proof-of-concept and early phase clinical trials.  The TRIO-US Network and the UCLA clinical oncology research program are managed in the UCLA JCCC Clinical Research Unit (CRU).  The CRU is headed by the Faculty Director and Division Chief of UCLA Hematology Oncology.  Daily oversight and management of the CRU is the responsibility of the Medical Director, Administrative Director, and Research Director.